ProCE Banner Activity

ABC Study: 5-Yr Survival Outcomes With Nivolumab ± Ipilimumab in Patients With Melanoma Brain Metastases

Slideset Download
Conference Coverage
An update of the ABC study at 5 years shows that nivolumab plus ipilimumab has enduring activity in patients with asymptomatic melanoma brain metastases.

Released: June 10, 2021

Expiration: June 09, 2022

No longer available for credit.

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie

Amgen, Inc.

AstraZeneca

Bristol Myers Squibb

Daiichi Sankyo, Inc.

Exelixis

Gilead Sciences, Inc.

GlaxoSmithKline

Ipsen Biopharmaceuticals Inc

Merck Sharp & Dohme Corp.

Novartis Pharmaceuticals Corporation

Pfizer, Inc.

Pharmacyclics LLC an AbbVie Company and Janssen Biotech Inc

Sanofi Genzyme